Raptiva Related Published Studies
Well-designed clinical trials related to Raptiva (Efalizumab)
Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. [2008.11]
Subcutaneous efalizumab is not effective in the treatment of alopecia areata. [2008.03]
Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial. [2008]
Efalizumab for the treatment of psoriatic arthritis. [2007.03]
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. [2006.07]
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. [2006.05]
Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. [2006.04]
Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. [2005.12.16]
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. [2005.09]
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. [2005.03]
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. [2005.01]
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. [2004.11]
Clinical benefits in patients with psoriasis after efalizumab therapy: clinical trials versus practice. [2004.09]
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. [2003.12.17]
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. [2003.11.20]
The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. [2003.08]
Well-designed clinical trials possibly related to Raptiva (Efalizumab)
Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies. [2008.07]
Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. [2006.08]
Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials. [2003.10.08]
Other research related to Raptiva (Efalizumab)
Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab. [2008.11]
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. [2008.08]
Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo. [2008.07]
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. [2008.06.10]
Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. [2008.06]
Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis. [2008.06]
Effect of Therapeutic Integrin (CD11a) Blockade with Efalizumab on Immune Responses to Model Antigens in Humans: Results of a Randomized, Single Blind Study. [2008.05.22]
Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. [2008.05]
Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. [2008.05]
Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. [2008.05]
Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. [2008.05]
Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. [2008.04]
Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. [2008.03]
DRESS syndrome caused by efalizumab. [2008.01]
[Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] [2008.01]
Infliximab then efalizumab, the 'hit and run' approach does not work. [2008]
Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label study. [2008]
Efalizumab-induced guttate psoriasis. Successful management and re-treatment. [2008]
Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy. [2008]
Case reports: practical experience with efalizumab in hand and foot psoriasis. [2007.12]
Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. [2007.11.14]
Treatment of hand and foot psoriasis with emphasis on efalizumab. [2007.11]
Multiple side effects of Efalizumab in a Saudi female with chronic persistent psoriasis followed by severe rebound after Efalizumab discontinuation. [2007.11]
Efalizumab-associated thrombocytopenia. [2007.10]
Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine. [2007.09]
Efalizumab in the treatment of discoid lupus erythematosus. [2007.07]
A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. [2007.07]
Efalizumab-associated papular psoriasis. [2007.07]
Efalizumab. [2007.07]
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. [2007.06]
Case reports: efalizumab-associated lymphoproliferative disease. [2007.06]
Lichen planus responding to efalizumab. [2007.05]
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. [2007.04]
Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. [2007.04]
Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute. [2007.04]
The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. [2007.04]
Efalizumab in routine use: a clinical experience. [2007.04]
Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient. [2007.03]
A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. [2007.03]
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. [2007.02.26]
Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. [2007.02]
Efalizumab for severe atopic dermatitis: a pilot study in adults. [2007.02]
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). [2007.01]
Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. [2007]
Exacerbation of pityriasis rubra pilaris under efalizumab therapy. [2007]
Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment. [2007]
CLinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial. [2006.11]
Etanercept and efalizumab for the treatment of psoriasis: a systematic review. [2006.11]
Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy. [2006.11]
Efalizumab-induced autoimmune pancytopenia. [2006.11]
Successful treatment of severe refractory atopic dermatitis with efalizumab. [2006.11]
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. [2006.10.26]
[Efalizumab--therapy of moderately severe to severe plaque-psoriasis in the dermatologist's practice] [2006.10]
Successful treatment of hand and foot psoriasis with efalizumab therapy. [2006.10]
Evaluation of efalizumab using safe psoriasis control. [2006.09.19]
Treatment of alopecia areata partim universalis with efalizumab. [2006.09]
[Efalizumab] [2006.08]
The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab. [2006.06]
[New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept] [2006.05.13]
Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. [2006.05]
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. [2006.04]
Efalizumab: a review of events reported during clinical trials and side effects. [2006.03]
Efalizumab in the treatment of psoriasis. [2006.03]
Rebound of psoriasis during treatment with efalizumab. [2006.01]
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. [2006.01]
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. [2006]
Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study. [2006]
Efalizumab: integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis. [2006]
Efalizumab, a reversible T-cell modulator for psoriasis. [2006]
A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence. [2006]
Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. [2006]
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. [2005.12]
Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II. [2005.12]
Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. [2005.09]
[Efalizumab. Long-term treatment of psoriasis] [2005.09]
Efalizumab for the treatment of moderate to severe plaque psoriasis. [2005.09]
Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. [2005.08.18]
Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. [2005.07]
Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. [2005.04]
Clinical considerations of efalizumab therapy in patients with psoriasis. [2005.03]
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. [2005.03]
Efalizumab: continuous therapy for chronic psoriasis. [2005.03]
|
